Avapritinib (Ayvakit, Blueprint Medicines), a novel agent that targets a specific mutation found in 90% of patients with systemic mastocytosis, reduces skin lesions and mast cell burden, according to ...

The predominant presentation of this mast-cell disorder is development of pruritic lesions—especially after rubbing or exposure to heat. A 2-year-old girl presented with a history of several brown ...

In September of 2000, the world's leading experts in MC met to discuss and present data at the "Year 2000 Working Conference on Mastocytosis," held in Vienna, Austria. Table 1 presents a uniform ...

Systemic mastocytosis is a myeloid neoplasm divided into six subcategories by the recent classification by WHO. It involves the accumulation of abnormal mast cells (MCs) in the skin, liver, spleen, ...

Plasma protein profiling may offer a more refined diagnostic tool for classifying mastocytosis subtypes and predicting disease course. The study emphasizes that mastocytosis is not solely driven by ...

A diagnosis of advanced systemic mastocytosis (advSM), a rare blood disorder in which too many mast cells accumulate in various parts of the body, can cause a range of strong emotions. AdvSM sometimes ...

Advanced systemic mastocytosis (advSM) is a rare and serious form of systemic mastocytosis, a blood disorder that involves the overproduction of mast cells. Mast cells are a type of white blood cell ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

Treatment with Ayvakit was associated with promising outcomes in patients with mastocytosis, according to findings from the PIONEER trial. Ayvakit (avapritinib) improved outcomes for patients with non ...

In the complex world of rare diseases, even small advances in understanding can make a profound difference in patients’ lives. Medscape Live is bringing back-to-back educational programs to San Diego ...